Business Context and Reporting Period
This Form 8-K, filed on June 23, 2023, by First Light Acquisition Group, Inc. ("FLAG"), reports material events occurring on June 16, 2023, regarding its proposed business combination with Calidi Biotherapeutics, Inc. ("Calidi"). The filing details a new financing round and amendments to the original Merger Agreement entered into on January 9, 2023.
Key Financial Metrics and Transaction Details
The filing focuses on a Series B Financing rather than historical operating results. Key financial terms include:
- Total Series B Commitment: $25,000,000 in aggregate Series B Preferred Stock.
- Investor Allocation:
- Jackson Investment Group, LLC: $12,500,000 total ($5,000,000 initial investment; $7,500,000 subsequent investment upon closing).
- Calidi Cure, LLC: $12,500,000 total ($5,000,000 by September 1, 2023 or closing; $7,500,000 upon closing).
- Founder Share Transfers: Sponsor and Metric agreed to transfer 389,968 Founder Shares to Jackson and one Founder Share for every $100 of Series B Preferred Stock acquired by Calidi Cure, LLC.
The filing does not provide Calidi's historical revenue, profit, cash flow, or debt metrics.
Material Changes and Amendments
On June 16, 2023, the parties executed Amendment No. 2 to the Merger Agreement and an amendment to the Sponsor Agreement. Key changes include:
- Unused Continuation Shares: FLAG may designate unused continuation shares as incentives for PIPE investments or other equity/debt-linked securities to facilitate closing or post-closing liquidity.
- Sponsor Incentive Securities: 25% of FLAG Class B Common Stock and 100% of Private Warrants held by the Sponsor and Metric may be used as incentives for PIPE investors, to pay transaction expenses, or reduce pre-closing operating costs. If unused, these securities will be cancelled.
- Merger Consideration Adjustment: The Series B Financing will result in an adjustment to the Merger Consideration and be included in the Minimum Cash Condition at closing.
- Fully Diluted Shares Definition: Amended to exclude vested in-the-money options from being treated as exercised for merger consideration calculations.
- Lock-Up Agreement: Jackson agreed to a lock-up on shares received as Merger Consideration until the earliest of six months post-closing, a 20-day trading period above $12.00/share (150 days post-closing), or a subsequent transaction.
Outlook, Risks, and Contingencies
The transaction remains contingent upon several factors, including shareholder approval of the business combination, the successful completion of the PIPE investment, and satisfaction of closing conditions. The filing includes standard forward-looking statements warning that actual results may differ due to risks such as:
- Termination of negotiations or failure to obtain regulatory approvals.
- Inability to complete the PIPE investment or secure necessary financing.
- Disruption of Calidi's operations due to the combination announcement.
- Changes in the pharmaceutical regulatory landscape and market conditions.
- Global conflicts and the impact of the COVID-19 pandemic.
Investor Verification Checklist
- Verify the final terms of the Series B Preferred Stock, including liquidation preferences and conversion rights, in the full Securities Purchase Agreement.
- Confirm the status of the Minimum Cash Condition at closing given the new financing structure.
- Review the definitive proxy statement/prospectus (Form S-4) for details on shareholder voting and redemption rights.
- Assess the impact of the amended "Fully Diluted Company Shares" definition on the final exchange ratio for Calidi shareholders.
- Monitor the timeline for the $7.5 million subsequent investments from both Jackson and Calidi Cure, LLC, which are contingent on the closing.